Micro
Emerging
Active
MDCXW FDA ilerlemesi ve klinik görünüm genişlemesi
Sınırlı kapsama alanına sahip yeni anlatı — henüz oluşuyor.
Puan
0,5
Hız
▲ 0,0
Makaleler
1
Kaynaklar
1
Duyarlılık Zaman Çizelgesi
Olay Zaman Çizelgesi
May 19, 2026
Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook
Neutral
Hipotezler
Pending
Vade: 18 Temmuz 2026
MDCXW trading volume will increase by at least 40% average daily volume in the 30 days following FDA progress announcement compared to 30-day pre-announcement baseline
Pending
Vade: 15 Kasım 2026
MDCXW will complete enrollment for at least one Phase 2 or Phase 3 clinical trial by end of Q2 2026, as evidenced by regulatory filings or company announcements
Pending
Vade: 17 Ağustos 2026
MDCXW stock price will appreciate by at least 15% within 90 days following positive FDA feedback on clinical trial progression announced in Q1 2026
Zaman Çizelgesi
Son GüncellemeMay 19, 2026